Moderna shares jump, set for eight straight day of gains

CureVac NV

22/05/2024 17:19

** Shares of Moderna  MRNA.O  rise 9.8% to $157.79, on track
for their eight straight session of advances, if gains hold;
other vaccine stocks also climb 
    ** Jefferies analyst Michael Yee points to Australia's first
human case of avian influenza in a child who authorities said
had been infected in India but made a full recovery
    ** Citizens JMP analyst Roy Buchanan, who covers CureVac,
says that if the H5N1 strain of bird flu becomes a greater
concern, there will be interest in accelerating bird flu vaccine
programs as happened with COVID-19
    ** Shares of Moderna  MRNA.O  up ~10%, Novavax  NVAX.O  up
~12.4% and CureVac  CVAC.O  up ~27.4% 
    ** BioNTech  BNTX.0  rise ~8.3%, while Pfizer  PFE.N  up 2%
    ** Including session's move, stock of CVAC and BNTX down 1%
to 4%, MRNA up ~58.6%, PFE up ~1.2% and NVAX shares have more
than tripled YTD   

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))